Latest

neuropsychopharmacology

·December 16, 2020·4 min read

How Does Ketamine Combat Depression?

4E-BPs proteins are key to unlocking ketamine's antidepressant effects. When 4E-BPs are absent in neurons, ketamine can not produce its antidepressant effect.

Featured Neuroscience Open Neuroscience Articles Psychology

·November 13, 2020·6 min read

Antidepressant May Prevent Severe COVID-19, Trial Suggests

A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.

This shows the shadow of a man in a tunnel

Featured Neuroscience Open Neuroscience Articles Psychology

·April 29, 2020·5 min read

Drug reduces risk of pedophiles re-offending

Degarelix, a drug that reduces testosterone levels, shows potential in the treatment of pedophilic disorder. Men with a history of child sexual abuse who took the drug had reduced overall sexual desire and decreased attraction toward children, with noticeable effects within two weeks.

This shows fish and the structure of NRF2

Featured Neuroscience Psychology

·April 13, 2020·2 min read

Discovery of a drug to rescue winter depression-like behavior

Fish model study found a potential target for the treatment of seasonal affective disorder (SAD). Researchers implicated NRF2 in seasonal depression and reported celastrol may help in the treatment of SAD.

This shows a brain and a swirly background

Brain Cancer Featured Neuroscience Psychology

·February 2, 2020·5 min read

Single dose of psilocybin reduces depression and anxiety for a year in cancer patients

A single dose of the psychedelic psilocybin reduces depression, anxiety, and feelings of hopelessness in cancer patients for 12 months after the drug is administered.

This shows a psychedelic face and flowers

Featured Neuroscience Psychology

·January 28, 2020·5 min read

Could psychedelics help treat mental health and resolve the climate crisis?

Numerous recent studies claim psychedelics, such as psilocybin, can help treat a range of mental health problems from depression to PTSD. Researchers investigate how psychedelics can help us become more "nature-connected" and increase a sense of environmental responsibility.

This shows two heads and a swirly background

Featured Neuroscience Psychology

·January 20, 2020·2 min read

New research confirms lingering mood benefit of psychedelics

Psychedelics, such as psilocybin, provide lasting improvements in mood and feelings of social connectedness, after the effect of the drug has worn off.

This shows psychedelic swirls around a person's head

Featured Neuroscience Psychology

·January 17, 2020·2 min read

Psychedelic drugs could help treat PTSD

Backing up previous research, a new study reveals psychedelics can have beneficial effects for treating PTSD when combined with traditional trauma-focused psychotherapy. Findings suggest MDMA assisted therapy is significantly more effective at treating patients with persistent PTSD than psychotherapy alone.

Featured Neuroscience Psychology

·December 11, 2019·7 min read

Rave new world: Scientists pry apart party drug’s therapeutic, addictive qualities

Researchers have distinguished two different molecular pathways responsible for addiction and the prosocial feelings generated by MDMA. The findings could lead to novel treatments for psychiatric disorders marked by withdrawal and social awkwardness.

Featured Neuroscience Open Neuroscience Articles Psychology

·September 20, 2019·6 min read

Common antidepressant may not reduce depression symptoms, but does reduce anxiety

Sertraline (Zoloft), a commonly prescribed SSRI antidepressant, may not be as effective at treating depression within 6 weeks as previously thought. However, the drug is effective for treating anxiety symptoms.

Featured Neuroscience Psychology

·September 1, 2019·5 min read

Psychedelic drugs: would you accept a prescription? It depends if you’ve tried them before

Numerous studies have linked controlled psychedelics to improvements in mental health conditions such as depression and PTSD. In March, the FDA approved Esketamine as a treatment for depression. However, with much stigma surrounding psychedelics, researchers question how many patients would take psychedelic medications if prescribed to them. According to a new study, 40% of people with no experience of psychedelics would be unlikely to take the prescription due to fears of 'brain damage' or a 'bad trip'.

Featured Neuroscience Psychology

·July 31, 2019·4 min read

Ketamine isn’t an opioid and treats depression in a unique way

A new study clarifies the mechanism behind how ketamine works as an antidepressant. Researchers say there is evidence to suggest ketamine binds to NMDA receptors, instead of opioid receptors. Reducing the belief that ketamine is an opioid may make patients with depression more open to using the treatment.